Company Description
HCW Biologics Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and diseases in the United States.
Its lead products include HCW11-018b, a novel, tetra-valent T-Cell engager; HCW11-040, a multifunctional fusion molecule that is a combination of cytokines and pembrolizumab; and HCW9302, injectable and interleukin 2 (IL-2) fusion protein complex, which is in phase 1 for alopecia areata diseases.
The company also develops HCW9201, a fusion protein designed as a reagent to use in the production of natural killer (NK) cell-based therapies; HCW9206, a fusion protein designed as a reagent to use in the production of CAR-therapies for the treatment of infectious diseases; and HCW11-006, an immune cell stimulator.
It has a license agreement with Wugen Inc. to develop cell therapy-based treatments; and a license, research and co-development agreement with WY Biotech Co., Ltd. for its preclinical molecules.
HCW Biologics Inc. was incorporated in 2018 and is headquartered in Miramar, Florida.
| Country | United States |
| Founded | 2018 |
| IPO Date | Jul 20, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 35 |
| CEO | Hing Wong |
Contact Details
Address: 2929 North Commerce Parkway Miramar, Florida 33025 United States | |
| Phone | 954 842 2024 |
| Website | hcwbiologics.com |
Stock Details
| Ticker Symbol | HCWB |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Share Class | Class A Shares |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $8.00 |
| CIK Code | 1828673 |
| CUSIP Number | 40423R204 |
| ISIN Number | US40423R2040 |
| Employer ID | 82-5024477 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Hing C. Wong Ph.D. | Founder, Chief Executive Officer, Director and Secretary |
| Rebecca Byam CPA, M.B.A. | Chief Financial Officer |
| Dr. Peter Rhode Ph.D. | Chief Scientific Officer and Vice President of Clinical Operations |
| Nicole Valdivieso Esq., J.D. | Vice President of Legal Affairs |
| Lee D. Flowers | Senior Vice President of Business Development |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jun 8, 2026 | D | Notice of Exempt Offering of Securities |
| Jun 8, 2026 | S-1 | General form for registration of securities under the Securities Act of 1933 |
| Jun 1, 2026 | 8-K | Current Report |
| May 27, 2026 | 8-K | Current Report |
| May 21, 2026 | 8-K | Current Report |
| May 18, 2026 | POS AM | Post-Effective amendments for registration statement |
| May 15, 2026 | SCHEDULE 13G/A | Filing |
| May 14, 2026 | 10-Q | Quarterly Report |
| May 14, 2026 | 8-K | Current Report |
| May 13, 2026 | POS AM | Post-Effective amendments for registration statement |